A monthly digest of research on company ingredients published in peer-reviewed journals
Study claim: People with high carbohydrate cravings demonstrated significantly greater reductions with chromium picolinate than a placebo group on four measures of depression: carbohydrate craving, appetite increase, increased eating and mood variation throughout the day.
Published: Docherty JP, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract 2005 Sep;11(5):302-14.
Abstract: In this double-blind, multicentre, eight-week replication study, 113 adult outpatients with atypical depression were randomised 2:1 to receive 600mcg/day chromium picolinate (CrPic), or placebo. Primary efficacy measures were the 29-item Hamilton Depression Rating Scale (HAM-D-29) and the Clinical Global Impressions Improvement Scale (CGI-I).
Of the 113 randomised patients, 110 (70 CrPic, 40 placebo) received at least one dose of study medication and completed at least one efficacy evaluation. In the evaluable population, mean age was 46 years, 69 per cent were female, 81 per cent were Caucasian, and mean body mass index was 29.7. There was no significant difference between the CrPic and placebo groups on the primary efficacy measures, with both groups showing significant improvement from baseline on total HAM-D-29 scores during the course of treatment (p
However, the CrPic group showed significant improvements from baseline compared with the placebo group on 4 HAM-D-29 items: appetite increase, increased eating, carbohydrate craving and diurnal variation of feelings. A supplemental analysis of data from the subset of 41 patients with high-carbohydrate craving (26 CrPic, 15 placebo; mean BMI = 31.1) showed that the CrPic patients had significantly greater response on total HAM-D-29 scores than the placebo group (65% vs 33%). The CrPic group also had significantly greater improvements on the following HAM-D-29 items: appetite increase, increased eating, carbohydrate craving, and level of libido. Chromium treatment was well tolerated.
Study results suggest that the main effect of chromium was on carbohydrate craving and appetite regulation in depressed patients, and that 600mcg chromium picolinate may be beneficial. Further studies are needed to evaluate chromium in depressed patients specifically selected for symptoms of increased appetite and carbohydrate craving as well as to determine whether a higher dose of chromium would have an effect on mood.
Potential applications: Available in supplemental form, Chromax can address insulin resistance and type 2 diabetes.
More info: www.nutrition21.com
+1 914 701 4500
Study claim: BioGest menopause relief cream is effective in reducing symptoms associated with menopause, including hot flashes, night sweats, muscle and joint aches, diminished physical strength and depleted energy levels.
Published: Steels E, et al. Reduction of symptoms associated with menopause: the efficacy of BioGest Menopause Relief Cream. Int J Naturopathic Med 2005 Summer.
Abstract: Hormone replacement therapy (HRT) is commonly prescribed for the physical, psychosocial and sexual symptoms of menopause and has been shown to improve cardiovascular health and prevent osteoporosis. However, there is evidence showing possible side effects of oestrogen or oestrogen/progestin therapy such as an increased incidence of endometrial and breast cancer, respectively. A significant proportion of menopausal women either do not commence or discontinue HRT use because of side effects, fear of cancer or advice from physicians.
This randomised, double-blind, placebo-controlled study of 23 menopausal women over a five-month period assessed the effectiveness of a natural product BioGest Menopause Relief cream for treating menopausal symptoms.
The product incorporates wild yam (Dioscorea villosa) herbal extract, the herbal essential oils of sage (Salvia officinalis) and rose geranium (Pelargonium graveolens), homeopathics (Progesterone 12C and wild yam 12C), linseed oil and vitamin E (d-alpha-tocopheryl acetate).
Study results indicate the cream is effective in treating menopausal symptoms, particularly vasomotor (hot flushes and night sweats) and physical symptoms, particularly those pertaining to stamina, energy and skin changes. Symptom relief persisted up to a month after treatment as well, indicating the one-month washout period was not sufficient and this should be taken into account in future studies.
Potential applications: BioLogic Health Solutions is based in Australia. MenoLogic is a proprietary liquid extract ingredient, which is available for licensing and co-branding opportunities in the United States.
More info: www.biologichealthus.com
+ 61 7 3315 2389
To submit newly published research on your company's ingredients, please email [email protected] for details.